AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
- Posted on October 5, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Oct 5 (Reuters) - Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in a late-stage study. US-listed shares of Genmab were up about 11% in afternoon trading. AbbVie shares rose 1.5%. • The study tested epcoritamab in combination with R-CHOP in newly
